Our clinical trials Clinical trials BELLINI M14-031 (Multiple Myeloma - Recruitment: CLOSED) Project Title A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy. Official Title A Phase III, Multicenter, Randomized, Double Blind Study of Bortezomib and Dexamethasone in Combination With Either Venetoclax or Placebo in Subjects With Relapsed or Refractory Multiple Myeloma Who Are Sensitive or Naïve to Proteasome Inhibitors. Project Summary This is a Phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of venetoclax plus bortezomib and dexamethasone in subjects with relapsed or refractory multiple myeloma who are considered sensitive or naïve to proteasome inhibitors and received 1 to 3 prior lines of therapy for multiple myeloma. Blood Disorder Multiple Myeloma Patient Recruitment Details Patient recruitment status: Closed Number of Patients (Globally) 289 participants.